User: prashantiyengar Topic: IP
Category: patents :: india
Last updated: Jul 23 2014 16:23 IST RSS 2.0
 
1 to 20 of 5,105    
NRI scientists express willingness to work in India: Government 23.7.2014 TOI: India
Several NRI scientists working abroad have expressed willingness to work in India as their confidence in the work environment in the country has increased, the Lok Sabha was informed on ...
Also found in: [+]
How India can reap the benefits of nanotech 22.7.2014 Rediff: Business
Nanotechnology has remarkable applications in a variety of spheres, including agriculture, animal husbandry and natural resources management.
Also found in: [+]
Major diabetes, cardiac drugs to become up to 35% cheaper 14.7.2014 TOI: India
Prices of expensive anti-diabetic and cardiac medicines will reduce by as much as 35% in the next few weeks, with the drug pricing regulator deciding to bring them under price ...
Also found in: [+]
Merck seeks to settle patent row with Glenmark 12.7.2014 TOI: Intl Business
In the long-winding patent battle on a widely-prescribed diabetes drug, Januvia (sitagliptin), multinational company Merck (MSD) has sought a settlement to end the dispute with generic company, Glenmark on the blockbuster drug.
Also found in: [+]
Lupin, Unichem Laboratories among global companies fined by European Commission 10.7.2014 ET: Pharma
As per the European Commission Anti-trust ruling, Lupin has been fined 40 million euros, while Unichem Laboratories 13.96 million euros.
Also found in: [+]
Bangalore scientists break bacteria's resistance to antibiotics 10.7.2014 TOI: India
Ever wondered why doctors increase the dosage of your medicine even when the nature of infection is the same as the previous time? This happens because infection-causing bacteria have mechanisms that resist drugs, just like our bodies resist ...
Also found in: [+]
Budget 2014: Industry hopes for measures aimed at reviving economy 8.7.2014 ET: Policy
The government has an opportunity to give a strong statement regarding bringing about economic stability, investment-friendly policies and tax reforms.
Also found in: [+]
Budget 2014: Modi govt should increase healthcare spends to 5% of GDP 7.7.2014 ET: Healthcare
The domestic Pharma segment is estimated to reach $49 billion by 2020, and the projected HR requirement to match this growth is estimated to be about 21,50,000 by 2020.
Also found in: [+]
Pharma sector demands lifting of MAT on SEZs 7.7.2014 Rediff: Business
Currently, the spend on R & D as a percentage of GDP is just 0.9%
Also found in: [+]
Budget 2014: Increase healthcare expenditure to 2.5% of GDP 1.7.2014 ET: Healthcare
All in all one hopes to see a Pharma friendly budget that can truly unleash the potential of this sector and take India to the next level.
Also found in: [+]
US pharma companies want dialogue with India on intellectual property rights 28.6.2014 TOI: India Business
While asserting there can be no compromise on IP protection issues, executives from top US pharma companies said that they are willing to work with India.
Also found in: [+]
US pharma companies want dialogue with India on IPRs 28.6.2014 Rediff: Business
Top executives of American pharma companies favour "dialogue" with India and "not confrontation" to address their concerns on key issues like the protection of intellectual property (IP) and clinical trials.
Also found in: [+]
Ranbaxy gets FDA approval for Novartis's Diovan generic 27.6.2014 DNA: India
Ranbaxy Laboratories Ltd (RANB.NS) has received approval from the United States. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment. Ranbaxy, which is in the process of being acquired by drugmaker Sun Pharmaceutical Industries Ltd (SUN.NS) for $3.2 billion, will be the first company to launch a copy of Diovan in the United States and will be entitled to six months of exclusivity to sell it. The drug should add about $200 million to Ranbaxy's sales and $100 million to its profit after tax during the exclusive sale period, said Praful Bohra, a senior research analyst at Mumbai-based brokerage Nirmal Bang. Swiss drugmaker Novartis lost its patent rights to its once best-selling Diovan in the United States at the end of 2012, but has avoided generic competition because of multiple production quality control problems at ...
Also found in: [+]
Ranbaxy gets FDA nod for Novartis generic pill 27.6.2014 TOI: India Business
Ranbaxy Laboratories Ltd has received approval from the US Food and Drug Administration to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.
Also found in: [+]
Reliance’s GenNext ventures backs surveillance solution company Videonetics 25.6.2014 ET: Software
The product, can be used for video surveillance, automated number plate recognition, red-light violation detection and facial recognition.
Also found in: [+]
Govt may extend price caps to more drugs 24.6.2014 TOI: India Business
The government is likely to raise the number of drugs deemed essential and subject to price caps, people directly involved in the process said.
Also found in: [+]
Health ministry may extend price caps to more drugs: Sources - Economic Times 24.6.2014 Google News India
Health ministry may extend price caps to more drugs: Sources Economic Times MUMBAI: India's health ministry has formed a committee that is meeting for the first time on Tuesday to consider raising the number of drugs deemed essential and subject to price caps, people directly involved in the process said. The panel will ...
Also found in: [+]
Modi govt plans to make medicines cheaper 24.6.2014 Rediff: Business
The health ministry has formed a committee to consider raising the number of drugs deemed essential and subject to price caps.
Also found in: [+]
US company denied patent on anti-cancer drug 24.6.2014 TOI: India Business
The Indian Patent Office has refused a patent on US firm Abraxis BioSciences' anti-cancer drug Abraxane, paving the way for domestic companies to launch affordable versions in the local market.
Also found in: [+]
Making science useful 24.6.2014 Telegraph: Opinion
Economies undergo turns of fortune: one moment they are riding the waves, and then they suddenly begin to drown. No one can predict when they will go up or down. Trade cycles have been going on for a couple of centuries. Many economists, consultants and politicians make a living predicting what would happen next. They are more often wrong than right; many will still remember how, whenever the economy turned down under his stewardship, the finance minister, P. Chidambaram, predicted it would recover soon. He was wrong every time, but that taught him nothing. The economy is doing badly just now, and our new rulers will soon start looking for an economic astrologer. But he will get it wrong just as often as his predecessors.
Also found in: [+]
1 to 20 of 5,105